CA3172627A1 - Method of treatment using anti-ccl24 antibody - Google Patents

Method of treatment using anti-ccl24 antibody Download PDF

Info

Publication number
CA3172627A1
CA3172627A1 CA3172627A CA3172627A CA3172627A1 CA 3172627 A1 CA3172627 A1 CA 3172627A1 CA 3172627 A CA3172627 A CA 3172627A CA 3172627 A CA3172627 A CA 3172627A CA 3172627 A1 CA3172627 A1 CA 3172627A1
Authority
CA
Canada
Prior art keywords
ccl24
monoclonal antibody
pharmaceutical composition
administration
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172627A
Other languages
English (en)
French (fr)
Inventor
Adi Mor
Arnon AHARON
Sharon Hashmueli
Michal SEGAL SALTO
Neta Barashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of CA3172627A1 publication Critical patent/CA3172627A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3172627A 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody Pending CA3172627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013793P 2020-04-22 2020-04-22
US63/013,793 2020-04-22
PCT/IL2021/050447 WO2021214759A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Publications (1)

Publication Number Publication Date
CA3172627A1 true CA3172627A1 (en) 2021-10-28

Family

ID=75787181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172627A Pending CA3172627A1 (en) 2020-04-22 2021-04-20 Method of treatment using anti-ccl24 antibody

Country Status (9)

Country Link
US (1) US20230235037A1 (enExample)
EP (1) EP4139352A1 (enExample)
JP (1) JP2023522907A (enExample)
KR (1) KR20230013037A (enExample)
CN (1) CN115427445A (enExample)
AU (1) AU2021259682A1 (enExample)
CA (1) CA3172627A1 (enExample)
IL (1) IL296579A (enExample)
WO (1) WO2021214759A1 (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US9067989B2 (en) 2009-01-28 2015-06-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
EP2490026A4 (en) * 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
DK3114139T3 (da) 2014-03-04 2022-09-12 Chemomab Ltd Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
US20180008707A1 (en) * 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
JP7155009B2 (ja) * 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
EP4652926A3 (en) * 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
IL251024A0 (en) 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
EP3660155A4 (en) * 2017-07-27 2021-04-07 Daiichi Sankyo Company, Limited ANTI-CD147 ANTIBODY
CN109745559A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Also Published As

Publication number Publication date
JP2023522907A (ja) 2023-06-01
EP4139352A1 (en) 2023-03-01
IL296579A (en) 2022-11-01
WO2021214759A1 (en) 2021-10-28
KR20230013037A (ko) 2023-01-26
US20230235037A1 (en) 2023-07-27
AU2021259682A1 (en) 2022-10-20
CN115427445A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
EA031489B1 (ru) Способ лечения ревматоидного артрита
US20250011416A1 (en) Methods for the treatment of cardiovascular disease
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
KR101581517B1 (ko) Tgf-알파 및 에피레굴린에 결합하는 항체
US20230235037A1 (en) Method of treatment using anti-ccl24 antibody
RU2832323C1 (ru) Способ лечения с использованием антитела против CCL24
JP2023502103A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
KR20220064998A (ko) 콜레스테롤 관련 질환을 예방하거나 치료하기 위한 방법에 있어서 항 pcsk9 항체의 용도
JP2025526402A (ja) 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
WO2025096435A1 (en) Treatment of complement-associated renal diseases
WO2025072725A1 (en) Methods for the treatment of cardiovascular disease
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
JP2023501465A (ja) 心血管疾患の治療のための内皮リパーゼ抗体
JP2010265213A (ja) 抗オートタキシン・モノクローナル抗体からなる間質性肺疾患治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250811

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260109

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317